Calling ARG-007 “glutamate inhibition” is misleading. it does not directly block glutamate receptors but prevents downstream excitotoxic signalling. For someone that spends so much time here you sure do get the basics a bit muddled up.
ARG are also nearing the end of a P2, which NYR is years away from. NYR also don't have any money to fund a P2.
“NYR is a complete prevention for stroke and heart attacks” is ridiculously false. It's shown PARTIAL protection of RAT hearts and brains.
NYR Price at posting:
13.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)